Cardiology Research and Practice最新文献

{"title":"Acute and Chronic Resistance Training Differentially Modulate Myocardial Angiogenesis-Related Gene Expression in Wistar Rats.","authors":"Putri Karisa, Nova Sylviana, Aziiz Mardanarian Rosdianto, Hanna Goenawan, Mas Rizky Anggun Adipurna Syamsunarno, Setiawan Setiawan","doi":"10.1155/crp/2976039","DOIUrl":"10.1155/crp/2976039","url":null,"abstract":"<p><p>Myocardial angiogenesis contributes to the maintenance of myocardial perfusion and cardiac function. Resistance training (RT) induces cardiovascular adaptations, but the myocardial transcriptional responses to acute RT (ART) and chronic RT (CRT) remain incompletely understood. This study compared the expression of angiogenesis- and metabolic adaptation-related genes in the left ventricle following a single RT bout and 8 weeks of repeated RT in healthy male Wistar rats. Twenty-four rats were randomized to three groups: sedentary control (CON) (<i>n</i> = 8), ART (one ladder-climbing session), or CRT (ladder-climbing 5 days/week for 8 weeks). RT was performed on a 1-m ladder inclined at 80° using progressive loads attached to the tail. Left-ventricular tissue was collected 1 h after the exercise bout in ART and 1 h after the final training session in CRT. Compared to CON, ART showed significantly higher HIF-1<i>α</i> and FSTL1 expression, whereas PGC-1<i>α</i> and VEGF did not differ significantly. CRT also showed significantly higher HIF-1<i>α</i> and FSTL1 expression than CON, together with significantly higher PGC-1<i>α</i> and VEGF expression. No significant differences were observed between ART and CRT for any of the genes examined. These findings demonstrate distinct myocardial transcriptional profiles following ART versus CRT, characterized by an HIF-1α- and FSTL1-associated response after a single bout and a PGC-1α- and VEGF-associated response following CRT.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"2976039"},"PeriodicalIF":2.1,"publicationDate":"2026-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13677139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149219979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship Between <i>Helicobacter pylori</i>, Trimethylamine-N-Oxide, and Carotid Plaque Formation Among Adult Health Checkup Population in China.","authors":"Fang Liu, Lina Zheng, Xia Cao, Yaoze Li, Xiangdong Xu, Yihan Zhou, Yue Wang, Yun Zhang, Xue Sun, Pei Peng, Jiangman Zhao","doi":"10.1155/crp/5468109","DOIUrl":"10.1155/crp/5468109","url":null,"abstract":"<p><strong>Background: </strong>Both trimethylamine-N-oxide (TMAO) and <i>Helicobacter pylori</i> (<i>H. pylori</i>) have been linked to atherosclerosis and carotid plaque development. This study examined the associations of <i>H. pylori</i> infection and plasma TMAO levels with carotid plaque in a health screening population.</p><p><strong>Methods: </strong>Between October 2022 and September 2023, 1779 participants undergoing routine health examinations, including carotid ultrasonography and <i>H. pylori</i> testing, were enrolled. Multivariable logistic regression was used to evaluate the association between <i>H. pylori</i> infection and carotid plaque. Inverse probability weighting (IPW) was applied to address selection bias in the TMAO subgroup, followed by weighted logistic regression analyses.</p><p><strong>Results: </strong>Carotid plaque was more prevalent among <i>H. pylori</i>-seropositive participants than among seronegative participants (53.96% vs. 40.37%, <i>p</i> < 0.001). In multivariable logistic regression analyses, <i>H. pylori</i> seropositivity remained significantly associated with carotid plaque after adjustment for demographic characteristics and cardiovascular risk factors, with odds ratios ranging from 3.099 to 3.392 across the adjusted models (all <i>p</i> < 0.001). Higher TMAO levels were associated with carotid plaque in unadjusted analyses and remained associated after adjustment for demographic and conventional cardiovascular risk factors; however, these associations were attenuated and became statistically non-significant after further adjustment for age. No significant association was observed between <i>H. pylori</i> seropositivity and plasma TMAO levels.</p><p><strong>Conclusions: </strong><i>H. pylori</i> infection was associated with carotid plaque in this cross-sectional study. The association between TMAO and carotid plaque appeared to be largely explained by age. Given the cross-sectional design, causal relationships cannot be inferred, and further prospective studies are warranted.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"5468109"},"PeriodicalIF":2.1,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13647107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Sizing Methods to Optimize Device Selection for Percutaneous Closure of Atrial Septal Defects.","authors":"Çağdaş Vural, Ali Baykan, Alper Doğan, Yunus Emre Kum, Özge Pamukçu Akay, Kazım Üzüm, Nazmi Narin","doi":"10.1155/crp/1663610","DOIUrl":"https://doi.org/10.1155/crp/1663610","url":null,"abstract":"<p><strong>Background and aims: </strong>Accurate sizing of atrial septal defects (ASDs) is crucial for appropriate device selection during percutaneous transcatheter closure. Despite the availability of multiple imaging and sizing techniques, no consensus exists on the optimal method for determining device size. This study aimed to compare preprocedural ASD measurements obtained using different techniques with the final device waist diameter and to identify the measurement method demonstrating the most favorable agreement and reproducibility.</p><p><strong>Methods: </strong>This retrospective study included 149 pediatric patients (64 males, 85 females) who underwent percutaneous transcatheter ASD closure. Preprocedural defect sizing was performed using transthoracic echocardiography (TTE), balloon sizing, and transesophageal echocardiography (TEE). TEE measurements were obtained in the four-chamber, aortic, and bicaval views. In addition to individual diameters, the arithmetic mean, cube root-derived diameter, and maximal TEE-measured diameter were calculated and compared with the final device waist diameter. The final device waist diameter, measured fluoroscopically after deployment, was used as the reference comparator, reflecting operator-selected device sizing rather than true anatomical defect dimensions.</p><p><strong>Results: </strong>Among TEE-based measurements, both the cube root-derived diameter and the arithmetic mean of TEE measurements demonstrated high reproducibility and favorable agreement with the final device waist diameter, with only marginal numerical differences between the two methods. Bland-Altman analysis supported these findings by showing minimal bias and narrow limits of agreement, whereas TTE and balloon sizing demonstrated lower, though statistically significant, concordance with the final device waist diameter.</p><p><strong>Conclusion: </strong>Combining multiple measurement techniques improves agreement with the operator-selected device size during percutaneous ASD closure. While TTE alone may be sufficient in patients with simple defects and adequate acoustic windows, integrated approaches incorporating TEE and multiaxis measurements showed favorable agreement characteristics, particularly in anatomically heterogeneous defects or resource-limited settings. These findings should be interpreted as reflecting agreement with operator-selected device sizing rather than anatomical sizing accuracy, given the inherent circularity of using implanted device size as a reference standard.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"1663610"},"PeriodicalIF":2.1,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13627864/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Routine CYP2C19 Genotyping, Antiplatelet Prescription Changes, and Clinical Outcomes After PCI in Chinese Patients With Coronary Heart Disease: A Single-Center Retrospective Study.","authors":"Dan Niu, Mei Zhang, Hong Guan","doi":"10.1155/crp/6267485","DOIUrl":"10.1155/crp/6267485","url":null,"abstract":"<p><strong>Background: </strong>CYP2C19 genotype can influence clopidogrel response, but the relationship between routine genotyping, real-world P2Y12 inhibitor prescribing, and clinical outcomes remains uncertain.</p><p><strong>Aims: </strong>To characterize P2Y12 inhibitor prescription patterns before and after routine CYP2C19 genotyping and to describe ischemic and bleeding outcomes in a retrospective real-world cohort.</p><p><strong>Methods: </strong>This single-center retrospective study included 364 adults with coronary heart disease who underwent percutaneous coronary intervention (PCI) from January to December 2023. During the study period, CYP2C19 genotyping was routinely performed as part of the hospital's antiplatelet management policy, and all 364 participants were genotyped. Prescription patterns before and after genotype results were compared; clinical outcome analyses were restricted to the 271 patients with complete linked postdischarge medication and outcome data.</p><p><strong>Results: </strong>Before genotyping, 273/364 patients (75.0%) received ticagrelor, and 91/364 (25.0%) received clopidogrel; after genotype results, 279/364 (76.6%) received clopidogrel, and 85/364 (23.4%) received ticagrelor. From the reported adjustment counts, 258 patients switched from ticagrelor to clopidogrel, 70 switched from clopidogrel to ticagrelor, and 36 remained on the same agent (exact McNemar <i>p</i> < 0.001). CYP2C19 genotypes were ∗1/∗1 in 132 (36.3%; normal metabolizer), ∗1/∗2 or ∗1/∗3 in 179 (49.2%; intermediate metabolizer), and two loss-of-function alleles in 53 (14.5%; poor metabolizer). In the 271-patient outcome subset, event counts were low, and treatment strata were highly imbalanced. Fisher exact comparisons were therefore considered exploratory, and no causal effect of genotyping or drug selection was inferred.</p><p><strong>Conclusions: </strong>Routine CYP2C19 genotyping was associated with a substantial change in P2Y12 inhibitor prescribing in this single-center cohort. Because treatment was physician-directed and outcome data were sparse and incomplete for the full cohort, the clinical event comparisons should be interpreted as exploratory rather than evidence that genotype-guided therapy reduced bleeding or ischemic events.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"6267485"},"PeriodicalIF":2.1,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13618363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Associations of the Naples Score for Clinical Outcomes in Patients With Acute Myocardial Infarction: A Systematic Review and a Prognostic Meta-Analysis.","authors":"Muhammad Sharjeel Abbas, Tayyaba Hameed, Román Rodríguez Milán, Hooria Sakina, Muhammad Junaid, Musab Riyan Ahmed, Mansoor Khan, Joao Victor Silva Correia, Warisha Kanwal, Ashfaq Ahmad, Kristine Santos, Anuraj Mambazhathu Sudhakaran, Hasibullah Aminpoor, Nehikhare Ekhator, Mrunalini Dandamudi","doi":"10.1155/crp/4613242","DOIUrl":"10.1155/crp/4613242","url":null,"abstract":"<p><strong>Background: </strong>The Naples Prognostic Score (NPS) is a composite inflammatory-nutritional index that integrates serum albumin, total cholesterol, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio to predict outcomes in acute myocardial infarction (MI); however, its independent prognostic value remains incompletely defined.</p><p><strong>Objective: </strong>To assess the correlation between the NPS and outcomes in patients with acute MI.</p><p><strong>Methods: </strong>We searched PubMed, Scopus, Cochrane, Embase, and Wiley Online Library for studies evaluating the NPS in patients with acute MI. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using random-effects models, and heterogeneity was assessed using the I² statistic.</p><p><strong>Results: </strong>Nine observational cohort studies comprising 15,998 patients with MI were analyzed. Higher NPS was associated with increased odds of all-cause mortality (OR 3.31; 95% CI: 1.62-6.77, <i>p</i> = 0.0130), no-reflow phenomenon (OR 1.40; 95% CI 1.11-1.76; <i>p</i> = 0.0248), and new-onset atrial fibrillation (OR 2.17; 95% CI: 1.62-2.91; <i>p</i> = 0.008). The association with in-hospital mortality did not reach statistical significance in the primary pooled analysis (OR 1.90; 95% CI: 0.66-5.44, <i>p</i> = 0.147), with substantial heterogeneity driven by a single influential study.</p><p><strong>Conclusion: </strong>Higher NPS was correlated with higher risk of all-cause mortality, no-reflow phenomenon, and new-onset atrial fibrillation in patients with acute MI. All estimates are based on observational data that have not been adjusted for any factors; there were three to four cohorts per outcome, and eight of nine studies were from one country. The findings are exploratory and do not warrant the use of NPS as a clinical risk stratification tool; future, adjusted, multinational validation is needed.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"4613242"},"PeriodicalIF":2.1,"publicationDate":"2026-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13615453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149058525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence for the Diagnosis of Transthyretin Amyloid Cardiomyopathy: A Systematic Review of Machine Learning Application.","authors":"Eyad Jamileh, Ahmed T Elmewafy, Muhammad Abdullah Qadeer, Zuhaib Zulfiqar, Kiran Kang, Kaveh Hosseini, Ibrahim Antoun","doi":"10.1155/crp/3289574","DOIUrl":"10.1155/crp/3289574","url":null,"abstract":"<p><strong>Background: </strong>Transthyretin amyloid cardiomyopathy (ATTR-CM) remains under-recognised, and earlier identification is increasingly important with disease-modifying therapy. Artificial intelligence (AI) applied to routine cardiovascular data may support screening, triage and diagnostic interpretation.</p><p><strong>Methods: </strong>MEDLINE, Embase, CINAHL, Web of Science and CENTRAL were searched from inception to August 2026 for studies evaluating AI/machine learning for ATTR-CM detection, screening or classification, including broader cardiac-amyloidosis models with separately extractable ATTR-specific performance and models detecting imaging phenotypes relevant to ATTR-CM screening. Risk of bias was assessed using an adapted QUADAS-2 framework, with AI-specific considerations informed by QUADAS-AI development work; selected TRIPOD + AI and CLAIM domains were assessed descriptively. Owing to substantial clinical and methodological heterogeneity, meta-analysis was not performed.</p><p><strong>Results: </strong>Twenty-eight primary reports were included, representing > 120,000 report-level participant entries, although overlapping cohorts precluded estimation of a unique-patient total. Performance varied by modality and task. AUCs ranged approximately 0.55-0.97 for ECG-containing models, 0.72-1.00 for echocardiography/POCUS and 0.70-0.85 for CT-based single-modality approaches; CMR differentiation of ATTR from AL achieved an AUC of 0.92. Nuclear-imaging models often showed high discrimination, including external-testing AUCs of 0.925-1.000, although several targeted tracer-uptake phenotypes rather than definitive ATTR-CM. Recurrent concerns included enriched populations, limited event counts, internal-only testing, threshold optimisation and incomplete calibration reporting.</p><p><strong>Conclusions: </strong>AI shows promise for ATTR-CM screening and automated interpretation, but reported discrimination should not be equated with real-world clinical performance. Prospective multicentre validation, calibration at realistic prevalence, transparent reporting and workflow-level evaluation are required before routine implementation.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"3289574"},"PeriodicalIF":2.1,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13586670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149007778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Burden of Ischemic Heart Disease and Ischemic Stroke, 1990-2023: Spatial Heterogeneity, SDI Inequalities, Pandemic-Era Inflections, and Scenario Forecasts to 2035 Using GBD 2023.","authors":"Haohao Chen, Boya Hu, Ziwen Xiong, Mengting Zhao, Bingxuan Chen, Jinhua Yang, Yali Wang, Ying Zeng, Fenfei Gao, De Cai","doi":"10.1155/crp/6248551","DOIUrl":"https://doi.org/10.1155/crp/6248551","url":null,"abstract":"<p><strong>Background: </strong>Ischemic heart disease (IHD) and ischemic stroke (IS) remain leading causes of death and disability, with substantial geographic and sociodemographic inequalities. We assessed long-term trends, sociodemographic index (SDI) disparities, COVID-19-period inflections, risk-factor profiles, and scenario forecasts using Global Burden of Disease (GBD) 2023 estimates.</p><p><strong>Methods: </strong>Using GBD 2023 data (1990-2023), we analyzed age-standardized incidence (ASIR), death (ASDR), and DALY rates (ASDALY) globally and across SDI quintiles. COVID-19 impacts were evaluated using segmented log-linear models (2010-2019 vs. 2020-2023), estimating the average annual percent change (AAPC) and counterfactual deviations extrapolating pre-COVID trends. Risk attribution used the GBD comparative risk assessment framework. ARIMA-based forecasts projected global ASDR/ASDALY to 2035, with S1 fitted to 2010-2019 and S2 to 2010-2023; 1990-start forecasts were assessed as sensitivity analyses.</p><p><strong>Results: </strong>In 2023, ASDRs varied widely across countries (IHD 24.9-441.0; IS 6.0-182.5 per 100,000). From 1990 to 2023, global ASDR declined for both diseases (IHD -38.2%; IS -53.1%), with an IHD SDI reversal (high SDI -52.8% vs. low SDI +13.4%). During 2020-2023, IHD mortality plateaued (AAPC 0.06%/year), whereas IS continued to decline but slowed (AAPC -1.48%/year). Forecasts to 2035 indicated a higher projected burden under S2 than S1.</p><p><strong>Conclusions: </strong>Progress in IHD and IS burden has been uneven, with widening SDI disparities and pandemic-era attenuation, underscoring the need for equitable and resilient prevention and care.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"6248551"},"PeriodicalIF":2.1,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13579108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148988116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential Contribution of <i>DES</i> (p.Leu88Met) and <i>MYH7</i> (p.Arg787His) Variants to Familial Restrictive Cardiomyopathy.","authors":"Mahrokh Bagherimoghaddam, Samira Kalayinia, Amir Farjam Fazelifar, Masomeh Jalilian, Sepideh Taghavi, Zahra Khajali, Majid Maleki, Ahmad Amin, Mahshid Malakootian","doi":"10.1155/crp/6363745","DOIUrl":"10.1155/crp/6363745","url":null,"abstract":"<p><strong>Background: </strong>Restrictive cardiomyopathy (RCM) is a rare, severe cardiac disease with a heterogeneous genetic basis. Both genetic and nongenetic factors contribute to RCM pathogenesis. Identifying the underlying molecular causes is important for diagnosis and family screening. In this study, we investigated the genetic basis of RCM in a 52-year-old woman with a family history of RCM and heart disease.</p><p><strong>Methods: </strong>Genetic predisposition was evaluated using whole-exome sequencing (WES). Candidate variants identified in the proband were validated by Sanger sequencing and interpreted using bioinformatics tools and the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) guidelines.</p><p><strong>Results: </strong>Two heterozygous missense variants were identified: a novel <i>DES</i> c.262C > A (p.Leu88Met) variant and a previously reported <i>MYH7</i> c.2360G > A (p.Arg787His) variant. The <i>DES</i> variant was absent from population databases and was classified as a variant of uncertain significance, whereas the <i>MYH7</i> variant has been reported in the cardiomyopathy spectrum, primarily in hypertrophic cardiomyopathy. Although both variants may be relevant to the participant's phenotype, their contribution remains uncertain without segregation and functional studies.</p><p><strong>Conclusion: </strong>These findings expand the spectrum of <i>DES</i> and <i>MYH7</i> variants observed in cardiomyopathy and highlight the need for further segregation and functional analyses to clarify their clinical significance in RCM. Identifying the genetic basis of RCM in this family may improve screening strategies and guide clinical management.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"6363745"},"PeriodicalIF":2.1,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13576896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148976010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between the Atherogenic Index of Plasma and the Occurrence of Slow Flow/No-Reflow in Patients With Acute Myocardial Infarction Undergoing Emergency Percutaneous Coronary Intervention.","authors":"Qinyu Sun, Yifan Deng, Weiyi Zhou, Zhoujun Huang, Shenghu He, Jing Zhang, Wei Zhou","doi":"10.1155/crp/4736031","DOIUrl":"10.1155/crp/4736031","url":null,"abstract":"<p><strong>Background: </strong>Percutaneous coronary intervention (PCI) is the primary reperfusion strategy for acute myocardial infarction (AMI); however, some patients develop slow flow/no-reflow (SF/NR) after the procedure, which adversely affects prognosis. Atherogenic index of plasma (AIP) is a reliable biomarker of cardiovascular risk, yet its predictive value for SF/NR following emergency PCI in AMI patients remains unclear.</p><p><strong>Objective: </strong>This study aimed to investigate the association between AIP and the occurrence of SF/NR in AMI patients undergoing emergency PCI.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 964 patients initially diagnosed with AMI who underwent PCI. The participants were categorized into SF/NR (<i>n</i> = 251) and normal flow (<i>n</i> = 713) groups on the basis of TIMI flow grade. Statistical analyses including LASSO regression, multivariate logistic regression, ROC curve analysis, RCS regression, subgroup analysis, and the development of a nomogram model were performed.</p><p><strong>Results: </strong>AIP was identified as an independent risk factor for postoperative SF/NR (OR = 3.184, <i>p</i> < 0.05). The AUC for AIP in the prediction of SF/NR was 0.737. Higher AIP quartiles were associated with increased risk, and a nonlinear relationship was observed. The constructed nomogram model demonstrated good predictive performance (AUC = 0.745), satisfactory calibration in internal validation, and favorable clinical utility. Subgroup analysis confirmed the consistent predictive ability of AIP across different strata.</p><p><strong>Conclusion: </strong>AIP may be associated with the risk of SF/NR after emergency PCI in AMI patients. Combined with white blood cell count and triglyceride levels, AIP could potentially assist in early identification of high-risk individuals, which warrants further validation in prospective studies. <b>Trial Registration:</b> Chinese Clinical Trial Registry: ChiCTR2500108501.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"4736031"},"PeriodicalIF":2.1,"publicationDate":"2026-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13570492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148954853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and Imaging Findings in 504 Cases With Left Ventricular Pseudoaneurysm Following Myocardial Infarction: A Comprehensive Systematic Review and Meta-Analysis.","authors":"Elmira Jafari Afshar, Amirhossein Tayebi, Parham Samimisedeh, Vahid Shahnavaz, Aryan Madady, Hadith Rastad, Neda Shafiabadi Hassani","doi":"10.1155/crp/9208154","DOIUrl":"10.1155/crp/9208154","url":null,"abstract":"<p><strong>Background: </strong>Left ventricular pseudoaneurysm (LVPA) is a rare but life-threatening complication of myocardial infarction (MI). We pooled clinical and imaging findings of post-MI LVPA reported in case reports/series and compared them with findings in post-MI left ventricular aneurysm (LVA).</p><p><strong>Method: </strong>We comprehensively searched the literature published since 1991 on online databases. Individual-level patient data (IPD) and aggregated-level data (AD) studies were combined through a two-stage meta-analysis method.</p><p><strong>Results: </strong>We identified 379 eligible articles on LVPA (<i>N</i> = 504 patients). LVPA patients were predominantly male (70.4%) with a mean age of 65.4 years (95% CI: 62.4, 68.4). The time interval between the last MI and the diagnosis of LVPA varied from one day to 20 years; 54.5% fell into the acute/subacute category. On echocardiography, the most frequent locations of LVPA were posterior (34.5%) and inferior (21.2%). The average dimensions were 5.7 and 7.3 cm. On MRI, late gadolinium enhancement, primarily pericardial, was observed in 84% of patients. Arrhythmia was more frequently observed in LVA than LVPA (33.8% vs. 1%). Echocardiography showed a lower diagnostic value in LVPA than LVA (sensitivity: 81.4% vs. 97.5%). A higher percentage of LVPA than the LVA group died during hospitalization (13.8% vs. 4.7%) or after discharge (17.5% vs. 9.0%).</p><p><strong>Conclusion: </strong>LVPA is probably located on the posterior and inferior segments in most patients, contrary to LVA, which mainly involves the anterior and apical segments. Arrhythmia is likely a common clinical finding in LVA but not LVPA. Echocardiography may not always detect LVPA in 20% of patients.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"9208154"},"PeriodicalIF":2.1,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13479120/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148788704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}